The receptor biology driving FGF21 therapeutic interest

FGF21 exerts its metabolic effects by activating a heterodimeric receptor complex comprising FGFR1c and the obligate co-receptor β-Klotho (KLB). Signaling through this complex drives glucose uptake, lipid oxidation, adiponectin secretion, and adipose tissue browning — a constellation of effects that makes it a compelling target for MASH, dyslipidemia, obesity, and type 2 diabetes. As academic literature from the University of Toronto confirms, FGF21 “plays important roles in regulating both glucose and lipid homeostasis via interacting with a heterodimeric receptor complex comprising FGF receptor 1 (FGFR1) and β-Klotho (KLB).”

The structural basis for receptor engagement is well-defined: C-terminal residues of FGF21 are primarily responsible for KLB binding, while N-terminal residues interact with FGFR1c. Structural studies from Indiana University using peptide-based alanine-scanning mapped the C-terminal residues critical for full bioactivity and designed enhanced KLB-binding agonist sequences — work that has directly informed analog engineering programs across the industry.

Transcriptional regulation of FGF21 is governed primarily by PPARα in the liver under fasting and fatty acid loading conditions, and by PPARγ as a secondary regulator in adipose tissue. The ER stress pathway also induces FGF21 expression via ATF4 and CHOP transcription factors, as characterized by researchers at Jilin University. This multi-pathway induction means FGF21 levels rise in metabolically stressed states — but chronically elevated endogenous levels are insufficient to overcome the disease burden in MASH and metabolic syndrome, reinforcing the therapeutic rationale for pharmacological FGF21 augmentation.

Downstream signaling through the FGFR1c/β-Klotho complex activates AMPK in hepatocytes, promoting fatty acid oxidation and inhibiting de novo lipogenesis to reduce intracellular triglyceride accumulation. A sex-dependent difference in FGF21 response has also been documented: research from AstraZeneca and the University of California Davis shows that FGF21’s hepatosteatosis-reducing effects in males are linked to downstream stimulation of adiponectin secretion via adrenergic receptor → cAMP → EPAC signaling from white adipose tissue, with female mice showing an attenuated response through this pathway.

Why wild-type FGF21 cannot be used as a drug

Wild-type FGF21 is disqualified as a direct therapeutic by three compounding liabilities: a plasma half-life of approximately 30–90 minutes, susceptibility to proteolytic inactivation by the serine protease fibroblast activation protein (FAP) at the Pro-171/Ser-172 cleavage site, and a propensity to aggregate during manufacture and storage. Each of these has driven a distinct engineering response.

FAP-mediated cleavage is the most clinically documented liability. According to research from Eli Lilly, in healthy human volunteers, 10–34% of circulating FGF21 was found to be cleaved after Pro-171, rendering it inactive. FAP cleaves at three sites in total: Pro-171 (FAP-mediated), and Pro-2 and Pro-4 at the N-terminus (attributed to dipeptidyl peptidases). This proteolytic vulnerability has been confirmed by research groups at both Tufts University and Eli Lilly, and has established FAP inhibition as a pharmacological strategy in its own right — an indirect route to amplifying endogenous active FGF21 without administering exogenous protein.

“In healthy human volunteers, 10–34% of circulating FGF21 was found to be cleaved after Pro-171 — establishing FAP-mediated inactivation as a clinically relevant liability that every engineering program must address.”

The FAP inhibitor talabostat, administered in diet-induced obese mice, produced profound decreases in body weight and adiposity, improved glucose tolerance, and elevated plasma intact FGF21 — with effects dependent on intact FGF21 signaling, as reported by the University of Cincinnati. This establishes FAP inhibition as a validated indirect FGF21-activating strategy, though it remains at a preclinical stage in this dataset.

The aggregation liability has been addressed through disulfide bond engineering. Eli Lilly’s LY2405319 incorporates an engineered disulfide bond (Leu118Cys/Ala134Cys) alongside the N-terminal HPIP deletion and C-terminal Ala-deletion to block FAP cleavage. This variant was designed for once-daily dosing and demonstrated improvement of metabolic parameters including glucose, body weight, cholesterol, and triglycerides in diabetic non-human primates.

Seven therapeutic modalities competing for the metabolic syndrome market

The FGF21 pipeline has diversified well beyond simple protein analogs. Seven distinct therapeutic modalities have emerged from the patent and academic literature, each addressing the half-life and stability challenges through different mechanisms — and each carrying a distinct IP and competitive profile.

1. Engineered protein muteins

Engineered FGF21 muteins are the most extensively documented modality in the retrieved dataset. Eli Lilly’s LY2405319 and Pfizer’s PF-05231023 have both been evaluated in human clinical trials. Amgen has published extensively on FGF21 muteins targeting proteolytic stability and aggregation resistance, including an Fc-FGF21 N-terminal fusion with two stabilizing point mutations. According to WIPO filings tracked in the dataset, multiple jurisdictions have granted or published claims in this space across the 2012–2025 period.

2. Fc-fusion proteins

Fusion to the Fc domain of IgG1 exploits FcRn-mediated recycling to extend half-life. Amgen’s research established that placing the Fc at the N-terminus is superior for preserving β-Klotho binding and in vivo potency. Akero Therapeutics’ AKR-001 (efruxifermin) achieved a half-life of 3–3.5 days, enabling weekly dosing. Novartis holds active EP patents on Fc-FGF21 variant fusion proteins updated as recently as 2024, and Yuhan Corporation holds EP patents targeting diabetes, obesity, dyslipidemia, metabolic syndrome, NAFLD, and NASH with a 2025 EP publication date.

3. PEGylated analogs

PEGylation has been applied to FGF21 by multiple groups. Ambrx developed site-specific PEGylated analogs using orthogonal biosynthesis with unnatural amino acids to enable chemically homogeneous PEG conjugation, demonstrating enhanced antidiabetic pharmacology in rodents. 89Bio Ltd. holds multiple active IL and EP patents on a distinct strategy: attaching a PEG moiety to a mutant FGF-21 via a glycosyl linker, intended to improve manufacturing homogeneity while preserving receptor-binding activity. Pfizer’s PF-05231023 is a long-acting FGF21 analog with distinct pharmacokinetic asymmetry between the intact C-terminus and N-terminus.

4. Albumin-binding derivatives

Novo Nordisk has filed multiple active IL and EP patents on FGF21 derivatives bearing an albumin binder of formula A-B-C-D-E covalently attached to the FGF21 protein, extending half-life through albumin recycling. Novo Nordisk also holds patents on FGF21 derivatives with engineered cysteine residues at positions 167–181 of mature human FGF21, with side chains at these cysteines displaying high potency toward FGF receptors.

5. Bispecific receptor agonists

Rather than delivering FGF21 protein, bispecific approaches target the receptor complex directly. Amgen demonstrated that bispecific Avimer polypeptides binding FGFR1c and β-Klotho with high affinity could mimic FGF21 activity in vitro and in obese cynomolgus monkeys with metabolic improvements comparable to FGF21. Regeneron Pharmaceuticals holds an active EP patent on bispecific antibody-based FGF21R agonists that simultaneously engage β-Klotho and FGFR1c, representing a modality fully differentiated from FGF21 protein analogs.

6. Combination fusion proteins

Sanofi holds multiple patents across IL, JP, AR, and SG jurisdictions on FGF21-GLP-1R fusion proteins and FGF21/GLP-1R agonist combinations for diabetes, dyslipidemia, obesity, and metabolic syndrome. This combination strategy aims to leverage complementary mechanisms — FGF21’s lipid and hepatic effects alongside GLP-1R’s glycemic and satiety effects — within a single molecular entity.

7. mRNA therapeutics

AstraZeneca reported preclinical data for subcutaneous delivery of mRNA encoding human FGF21 in diet-induced obese mice, achieving therapeutic plasma FGF21 levels with improved pharmacokinetic/pharmacodynamic coverage versus recombinant protein. This was described as the first example of subcutaneous mRNA therapy demonstrating preclinical efficacy in a disease-relevant metabolic model. This modality remains preclinical based on the retrieved dataset, according to standards tracked by organizations such as the FDA for novel modality development.

Clinical and translational signals from the pipeline

The most advanced clinical signal in the retrieved dataset comes from Akero Therapeutics’ AKR-001 (efruxifermin), an Fc-FGF21 fusion protein that achieved a half-life of 3–3.5 days — enabling once-weekly (QW) dosing in patients. In a Phase 1 multiple ascending dose study in type 2 diabetes patients, AKR-001 demonstrated pharmacodynamic effects on serum markers of insulin sensitivity and lipid profiles with acceptable tolerability at doses up to 70 mg. The peak-to-trough ratio under steady-state conditions was approximately 2 with QW dosing, enabled by the 3–3.5 day half-life.

Bristol-Myers Squibb’s pegbelfermin (BMS-986036) represents the most clinically advanced program by patent coverage in this dataset, with BMS holding active and pending patents specifically covering modified FGF-21 for NASH treatment. The BMS patent introduces a key translational innovation: serum Pro-C3 (a type III collagen propeptide) as a pharmacodynamic biomarker. The patent establishes serum Pro-C3 greater than 10 ng/mL as a threshold for NASH patient stratification, and a decrease in Pro-C3 as an on-treatment signal of FGF21 anti-fibrotic efficacy. This represents a meaningful advance in translational biomarker development alongside FGF21 analog design, and aligns with standards being developed by organizations such as the NIH for non-invasive NASH biomarker validation.

LY2405319 (Eli Lilly) and PF-05231023 (Pfizer) have also been evaluated in human clinical trials based on review-level papers in the dataset. Pfizer’s PF-05231023 is described in preclinical PK/PD modeling studies as a long-acting FGF21 analog with distinct pharmacokinetic asymmetry between the intact C-terminus and N-terminus — a property that complicates standard bioanalytical approaches but informs dosing interval design.

AstraZeneca’s mRNA FGF21 program and the FAP inhibitor approach (talabostat, University of Cincinnati) remain at preclinical stages based on retrieved data. The mRNA approach was described as the first example of subcutaneous mRNA therapy demonstrating preclinical efficacy in a disease-relevant metabolic model — a notable milestone given the broader interest in mRNA platforms for metabolic diseases, as tracked by the EMA in its advanced therapy frameworks.

Who holds the key IP positions in FGF21 drug development

Commercial IP activity in the FGF21 space is concentrated among large pharmaceutical companies and specialized biotechs, with academic institutions contributing predominantly to mechanistic and translational biology rather than patent filings. Amgen is the most prominently represented commercial innovator in the retrieved dataset by both patent and publication count, holding active IL patents on FGF21 mutants (2015) and having published extensively on Fc-FGF21 fusions, bispecific FGFR1c/β-Klotho Avimers, and adipose tissue biology.

Novo Nordisk holds a broad-coverage IP position in FGF21 half-life extension chemistry, with multiple active IL and EP patents on albumin-binding derivatives (EP, 2018) and cysteine-directed side chains at positions 167–181 of mature human FGF21 (IL, 2022). This dual-strategy patent portfolio — covering both the linker chemistry and the attachment site engineering — represents a substantial IP moat in the albumin-binding modality space.

Sanofi’s IP position is differentiated by its focus on combination modalities: the company holds patents across IL, JP, AR, and SG jurisdictions on FGF21-GLP-1R fusion proteins and FGF21/GLP-1R agonist combinations, targeting diabetes, dyslipidemia, obesity, and metabolic syndrome. This multi-jurisdiction coverage across four patent offices reflects a global commercial strategy for the combination approach. Patent data tracked through the EPO confirms active EP coverage for several of these programs.

89Bio Ltd. holds a focused biotech IP strategy in next-generation PEGylation chemistry, with active IL and EP patents on PEG-glycosyl-conjugated mutant FGF-21 peptides (EP, 2022) for NASH, T2D, and metabolic syndrome. Regeneron’s EP patent on bispecific antibody FGF21R agonists (2021) represents the only major IP position in the receptor agonist modality that does not require delivering FGF21 protein at all. Novartis’ EP patent on Fc-FGF21 variants was updated as recently as 2024, signaling continued active prosecution in this space. Yuhan Corporation’s EP patent on long-acting FGF21 fusion proteins carries a 2025 publication date — the most recent filing in the dataset.

“Bristol-Myers Squibb’s patent on modified FGF-21 for NASH establishes serum Pro-C3 greater than 10 ng/mL as a patient stratification threshold — a translational biomarker strategy advancing alongside the molecule itself.”

Academic contributions to this field span institutions including the University of Toronto, Kyoto University, University of Hong Kong, McGill University, Tufts University, Indiana University, and the University of Alabama — predominantly contributing mechanistic papers on receptor biology, proteolytic processing, and downstream signaling rather than patent filings. The Indiana University structural mapping of C-terminal KLB-binding residues is particularly notable for its direct translational relevance to analog design. These academic contributions form the scientific foundation upon which commercial IP programs build, consistent with innovation patterns documented by the OECD in biomedical research ecosystems.

The overall IP landscape reflects a field in active commercial prosecution, with no single assignee holding a dominant position across all modalities. The diversity of half-life extension strategies (Fc-fusion, PEGylation, albumin-binding) and the emergence of receptor-targeted approaches (bispecific agonists) and novel delivery modalities (mRNA) suggests that freedom-to-operate analysis will be modality-specific — and that the competitive dynamics will play out differently across each engineering approach. Explore the full patent landscape and competitive intelligence through PatSnap’s drug discovery intelligence platform.